A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-02

Study Completion Date

2023-01-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, single-dose, randomized, three-period, two-treatment, threesequence, crossover, PK, partial replicate, and comparative bioavailability study. This study may be conducted in groups. The same protocol requirements and procedures will be followed for each group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets

NCT03151720

Healthy

COMPLETED PHASE1

Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions

NCT00837915

Healthy

COMPLETED NA

To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets

NCT00946608

Allergy

COMPLETED PHASE1

Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions

NCT00776217

Healthy

COMPLETED NA

A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets

NCT03196531

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will allow for the determination of the PK and intra-subject variability of rupatadine and metabolites. In addition, this study will compare the bioavailability of the rupatadine formulation (Drug Product 1) to a FDA-approved reference product (Clarinex®) (Drug Product 2) as far as the rupatadine metabolite desloratadine, and the derived compounds, is concerned.

Comparative bioavailability between Drug Product 1 and Drug Product 2 will be determined by a statistical comparison of the AUCt, AUCinf, and Cmax parameters for desloratadine (UR-12790), 3-OH desloratadine (UR-12788), 5-OH desloratadine (UR-12767), 6-OH desloratadine (UR-12766), and 3-OH-glucuronide-desloratadine (UR-12335).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This is an open-label, single-dose, randomized, three-period, two-treatment, threesequence, crossover, PK, partial replicate, and comparative bioavailability study.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence 1

Subjects will take comparator and active drug at different study periods Treatment sequence AAB

Group Type OTHER

Rupatadine

Intervention Type DRUG

Oral single dose 10 mg tablet

Sequence 2

Treatment sequence ABA

Group Type OTHER

Rupatadine

Intervention Type DRUG

Oral single dose 10 mg tablet

Sequence 3

Treatment sequence BAA

Group Type OTHER

Rupatadine

Intervention Type DRUG

Oral single dose 10 mg tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rupatadine

Oral single dose 10 mg tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pafinur

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy, non-smoking, male and female subjects, 18 years of age or older.
2. BMI ≥19 kg/m2.
3. Females may be of childbearing or non-childbearing potential:

* Childbearing potential:

o Physically capable of becoming pregnant
* Non-childbearing potential:

* Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or
* Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause).
4. QTc ≤450 msec \[corrected using Bazett's formula (QTcB)\].
5. Willing to use acceptable, effective methods of contraception for the duration of the entire study.
6. Able to tolerate venipuncture.
7. Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion Criteria

1. Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
2. Known or suspected carcinoma.
3. Known history or presence of hypersensitivity or idiosyncratic reaction to rupatadine, desloratadine, or any other drug substances with similar activity.
4. Known history or presence of clinically significant angioedema.
5. Known history or presence of clinically significant lactose, galactose, or fructose intolerance.
6. Any acute illness (e.g. cold, acute infection) which is considered significant by the Investigator and that has not resolved within 7 days before the first drug administration.
7. Presence of hepatic or renal dysfunction.
8. Presence of hay fever, seasonal allergy, or rhinitis.
9. Presence of sinusitis.
10. Presence of nasal symptoms (e.g., blocked and/or runny nose).
11. History of atopic allergy (e.g., asthma, urticaria, eczematous dermatitis).
12. History of drug or alcohol addiction requiring treatment.
13. Positive test result for COVID-19 Ag, HIV, Hepatitis B surface Ag, or Hepatitis C Ab.
14. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
15. Difficulty fasting or consuming standard meals.
16. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
17. Females who:

* Have used implanted, injected, intravaginal, or intrauterine hormonal contraceptives within 6 months prior to drug administration;
* Have used oral or transdermal hormonal contraceptives within 21 days prior to drug administration;
* Are pregnant (serum hCG consistent with pregnancy); or
* Are lactating.
18. Donation or loss of whole blood (including clinical trials):

* ≥50 mL and \<500 mL within 30 days prior to drug administration;
* ≥500 mL within 56 days prior to drug administration.
19. Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
20. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
21. Have had a tattoo or body piercing within 30 days prior to drug administration.
22. Have clinically significant findings in vital signs measurements.
23. Have clinically significant findings in a 12-lead ECG.
24. Have clinically significant abnormal laboratory values.
25. Have significant diseases.
26. Have clinically significant findings from a physical examination.
27. Use of any of the following within 30 days prior to drug administration:

* Antihistamines;
* CYP3A4 substrates with a narrow therapeutic index (e.g., ciclosporin, tacrolimus, sirolimus, everolimus, cisapride);
* Drugs known to alter gastrointestinal pH/movement (e.g., cimetidine, omeprazole, ranitidine);
* Drugs known to prolong QTc;
* Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism, specifically CYP 2C9, 2C19, 2D6, and 3A4 (e.g., ketoconazole, itraconazole, fluconazole, posaconazole, voriconazole, clarithromycin, azithromycin, erythromycin, diltiazem, HIV protease inhibitors, nefazodone);
* Fluoxetine; or
* Statins.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes